◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Home › All stocks › B › BMRN

Biomarin Pharmaceutical Inc (BMRN) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-09-19

Biomarin Pharmaceutical Inc (BMRN) operates in the BIOTECHNOLOGY industry and is headquartered in San Rafael, United States with about 3,221 employees. Its market capitalization is roughly $12 billion. In the fiscal year ended 2025-12-31, BMRN reported $3.2B in revenue and $349M in net income.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally.

Interactive charts & full statements → Open the BMRN valuation workbench →

BMRN Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Revenue	$3.4B	$3.2B	$2.9B	$2.4B	$2.1B	$1.8B	$1.9B	$1.7B	$1.5B	$1.3B	$1.1B	$890M	$749M	$548M	$501M	$441M	$376M	$325M	$296M	$122M	$84M
Gross Profit	$2.6B	$2.5B	$2.3B	$1.9B	$1.6B	$1.4B	$1.3B	$1.3B	$1.2B	$1.1B	$907M	$738M	$627M	$460M	$409M	$357M	$306M	$259M	$244M	$103M	$75M
Gross Margin %	75.5%	77.1%	79.7%	78.0%	76.0%	74.5%	71.8%	78.9%	78.9%	81.6%	81.2%	82.9%	83.7%	83.9%	81.7%	81.0%	81.3%	79.7%	82.3%	84.9%	89.6%
Operating Income (EBIT)	$273M	$533M	$484M	$186M	$161M	($82M)	($43M)	($100M)	($124M)	($15M)	($803M)	($111M)	($93M)	($156M)	($110M)	($34M)	$1M	$16M	$40M	($57M)	($25M)
Operating Margin %	8.0%	16.6%	17.0%	7.7%	7.7%	-4.5%	-2.3%	-5.9%	-8.3%	-1.1%	-71.9%	-12.4%	-12.4%	-28.4%	-22.0%	-7.7%	0.1%	5.1%	13.4%	-47.1%	-29.3%
Net Income	$73M	$349M	$427M	$168M	$142M	($64M)	$854M	($24M)	($77M)	($117M)	($630M)	($172M)	($134M)	($176M)	($114M)	($54M)	$206M	$0M	$31M	($16M)	($29M)
Net Margin %	2.1%	10.8%	15.0%	6.9%	6.8%	-3.5%	45.9%	-1.4%	-5.2%	-8.9%	-56.4%	-19.3%	-17.9%	-32.1%	-22.8%	-12.2%	54.7%	-0.1%	10.4%	-13.0%	-33.9%
EBITDA	—	$573M	$651M	$307M	$265M	$47M	$84M	$32M	($3M)	$91M	($698M)	($73M)	($46M)	($131M)	($67M)	$0M	$17M	$36M	$67M	($53M)	($15M)
Earnings Per Share (EPS)	$0.36	$1.77	$2.17	$0.87	$0.75	$-0.35	$4.46	$-0.13	$-0.44	$-0.67	$-3.79	$-1.07	$-0.92	$-1.28	$-0.95	$-0.48	$1.64	$-0.00	$0.30	$-0.16	$-0.34
Shares Outstanding (M)	—	197M	197M	192M	189M	183M	192M	179M	177M	174M	166M	160M	146M	138M	120M	112M	126M	100M	104M	96M	85M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BMRN Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$990M	$766M	$875M	$776M	$825M	$745M	$747M	$746M	$712M
Gross Profit	$787M	$571M	$579M	$636M	$675M	$594M	$611M	$557M	$582M
Gross Margin %	79.5%	74.6%	66.3%	82.0%	81.8%	79.7%	81.8%	74.7%	81.7%
Operating Income (EBIT)	$111M	$130M	$79M	($47M)	$277M	$224M	$161M	$114M	$120M
Operating Margin %	11.2%	16.9%	9.1%	-6.0%	33.6%	30.0%	21.6%	15.3%	16.9%
Net Income	$45M	$106M	($47M)	($31M)	$241M	$186M	$125M	$106M	$107M
Net Margin %	4.5%	13.8%	-5.3%	-4.0%	29.1%	24.9%	16.7%	14.2%	15.0%
EBITDA	—	$173M	($4M)	($5M)	$319M	$263M	$195M	$156M	$162M
Earnings Per Share (EPS)	$0.23	$0.53	$-0.24	$-0.16	$1.22	$0.95	$0.64	$0.54	$0.53
Shares Outstanding (M)	—	198M	197M	192M	197M	196M	197M	197M	201M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BMRN Free Cash Flow History

Cash flow	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Cash from Operations (CFO)	$858M	$828M	$573M	$159M	$176M	$305M	$85M	$48M	$20M	($9M)	($228M)	($222M)	($74M)	($60M)	$18M	$19M	$19M	$88M	($9M)	($34M)	($50M)
Capital Expenditures (CapEx)	$124M	$103M	$97M	$108M	$121M	$119M	$138M	$145M	$145M	$199M	$148M	$228M	$119M	$65M	$45M	$154M	$49M	$90M	$56M	$22M	$25M
Free Cash Flow (FCF)	$733M	$725M	$475M	$52M	$55M	$185M	($52M)	($97M)	($124M)	($208M)	($376M)	($449M)	($192M)	($125M)	($27M)	($135M)	($31M)	($2M)	($66M)	($57M)	($75M)
FCF Margin %	21.5%	22.5%	16.7%	2.1%	2.6%	10.0%	-2.8%	-5.7%	-8.3%	-15.8%	-33.7%	-50.5%	-25.7%	-22.8%	-5.4%	-30.7%	-8.2%	-0.6%	-22.1%	-46.8%	-88.7%
Dividends Paid	—	—	—	—	$15M	$3M	$72M	$11M	—	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BMRN Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	$168M	$221M	$100M	$369M	$185M	$174M	$186M	$221M	$119M
Capital Expenditures (CapEx)	$34M	$21M	$41M	$28M	$17M	$17M	$20M	$21M	$22M
Free Cash Flow (FCF)	$134M	$200M	$59M	$340M	$168M	$158M	$165M	$200M	$97M
FCF Margin %	13.5%	26.1%	6.7%	43.8%	20.4%	21.1%	22.1%	26.9%	13.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BMRN Balance Sheet History

Balance sheet	2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
Total Assets	$11.7B	$7.6B	$7.0B	$6.8B	$6.4B	$6.0B	$5.8B	$4.7B	$4.4B	$4.6B	$4.0B	$3.7B	$2.5B	$2.2B	$1.6B	$1.3B	$1.3B	$917M	$907M	$815M	$463M
Cash & Cash Equivalents	$874M	$1.3B	$943M	$755M	$725M	$587M	$649M	$437M	$494M	$598M	$408M	$397M	$875M	$569M	$181M	$46M	$88M	$167M	$223M	$228M	$89M
Total Liabilities	$5.4B	$1.5B	$1.3B	$1.9B	$1.8B	$1.7B	$1.7B	$1.6B	$1.5B	$1.8B	$1.3B	$1.3B	$963M	$903M	$553M	$533M	$545M	$595M	$630M	$628M	$346M
Total Debt (Short + Long-Term)	$4.2B	$606M	$618M	$1.1B	$1.1B	$1.1B	$1.1B	$859M	$830M	$1.2B	$683M	$1.3B	$1.3B	$656M	$348M	$348M	$453M	$497M	$639M	$570M	$299M
Total Shareholders' Equity	$6.3B	$6.1B	$5.7B	$5.0B	$4.6B	$4.3B	$4.1B	$3.1B	$3.0B	$2.8B	$2.8B	$2.4B	$1.5B	$1.3B	$1.0B	$773M	$717M	$322M	$277M	$188M	$118M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BMRN viewer.

BMRN Metric Deep Dives

Other Companies in BIOTECHNOLOGY

EXEL · Exelixis Inc — $14 billion
SMMT · Summit Therapeutics PLC — $14 billion
BBIO · BridgeBio Pharma Inc — $13 billion
HALO · Halozyme Therapeutics Inc — $13 billion
MDGL · Madrigal Pharmaceuticals Inc — $12 billion
CORT · Corcept Therapeutics Incorporated — $12 billion
AXSM · Axsome Therapeutics Inc — $11 billion
APGE · Apogee Therapeutics, Inc. Common Stock — $10 billion

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← BMRC All “B” companies BMS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.